Ownership and insider activity for Protagenic Therapeutics, Inc. (PTIX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Protagenic Therapeutics, Inc. operates as a pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. Protagenic Therapeutics, Inc. was founded in 2004 and is based in Santa Barbara, California.
Price
| Price | $0.84 |
| Market Cap | $2M |
| Exchange | OTC |
| Country | US |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.1M | $399687 | $362486 | $798623 | $671091 | $541171 | $215189 | $1.3M | $1.8M | $2.2M |
| Short-term Investments | 0 | $1.3M | $250388 | 0 | 0 | $9.8M | $7.8M | $2.8M | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $41523 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $1074 |
| Total Current Assets | $3.2M | $1.8M | $696273 | $841977 | $879247 | $11.1M | $8.0M | $4.2M | $1.9M | $2.3M |
| Property, Plant & Equipment | $1097 | $1022 | $611 | $296 | 0 | 0 | $1775 | $123332 | $73046 | $38836 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $2.1M |
| Total Assets | $3.2M | $1.8M | $696884 | $842273 | $879247 | $11.1M | $8.0M | $4.3M | $2.0M | $2.1M |
| Accounts Payable | $13400 | $10965 | $10048 | $163029 | $141860 | $278957 | $155486 | $113802 | $102962 | $2.0M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | $344230 | 0 | 0 | $3.2M |
| Total Current Liabilities | $684857 | $561692 | $907767 | $1.2M | $655187 | $799535 | $1.1M | $655252 | $942759 | $6.8M |
| Long-term Debt | 0 | 0 | 0 | $279370 | $1.4M | $318433 | 0 | 0 | 0 | 0 |
| Total Liabilities | $684857 | $561692 | $907767 | $1.5M | $2.0M | $1.1M | $1.1M | $655252 | $942759 | $6.8M |
| Retained Earnings | -$8.6M | -$10.8M | -$13.4M | -$15.2M | -$17.7M | -$22.2M | -$25.8M | -$30.8M | -$36.3M | -$9.1M |
| Total Equity | $2.5M | $1.2M | -$210883 | -$634366 | -$1.1M | $9.9M | $6.9M | $3.7M | $1.0M | -$2.4M |
| Total Debt | 0 | 0 | 0 | $279370 | $1.4M | $318433 | $344230 | 0 | 0 | $3.2M |
| Net Debt | -$3.1M | -$1.7M | -$612874 | -$519253 | $702705 | -$10.1M | -$7.6M | -$4.1M | -$1.8M | $943263 |
| Working Capital | $2.5M | $1.2M | -$211494 | -$355292 | $224060 | $10.3M | $6.9M | $3.5M | $940108 | -$4.5M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 0.66 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -17.34 |
Profitability
| Return on Equity | -794.18% |
| Return on Invested Capital | -419.98% |
| Return on Assets | 261.82% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ARTL · CARM · GTBP · INDP · LIPO · PBM · REVB
Explore sector: Healthcare · Biotechnology
More sections of PTIX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks